Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

PD-1

TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 3 Jun 2026
A-BRAVE: time-of-day immunotherapy administration in early-stage TNBC
1:58
A-BRAVE: time-of-day immunotherapy administration in early-stage TNBC
Shipra Gandhi • 3 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 3 Jun 2026
KEYNOTE-522: final analysis of pembrolizumab and chemotherapy in TNBC
4:12
KEYNOTE-522: final analysis of pembrolizumab and chemotherapy in TNBC
Peter Schmid • 3 Jun 2026
Lung cancer at ASCO 2026: LIBRETTO-432, DeLLphi-304 & ALCHEMIST
6:03
Lung cancer at ASCO 2026: LIBRETTO-432, DeLLphi-304 & ALCHEMIST
Abdul Rafeh Naqash • 3 Jun 2026
Neoadjuvant cemiplimab in HHI-naive head & neck basal cell carcinoma
1:21
Neoadjuvant cemiplimab in HHI-naive head & neck basal cell carcinoma
Hannah Kenny • 31 May 2026
SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
1:38
SYNERGY: nenocorilant and nivolumab in advanced solid malignancies
Omid Hamid • 31 May 2026
mRNA-4359 and pembrolizumab shows activity in advanced melanoma
2:26
mRNA-4359 and pembrolizumab shows activity in advanced melanoma
Allison Betof Warner • 6 May 2026
PLN-101095 shows promise in immune checkpoint inhibitor-resistant tumors
6:18
PLN-101095 shows promise in immune checkpoint inhibitor-resistant tumors
Timothy Yap • 24 Apr 2026
Overcoming resistance to frontline immunotherapy in kidney cancer
0:57
Overcoming resistance to frontline immunotherapy in kidney cancer
Tian Zhang • 13 Mar 2026
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
1:51
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
Tian Zhang • 13 Mar 2026
Inclusion criteria of the EV-PRIME trial in muscle-invasive bladder cancer
3:26
Inclusion criteria of the EV-PRIME trial in muscle-invasive bladder cancer
Vadim Koshkin • 9 Mar 2026
EV-PRIME: enfortumab vedotin, pembrolizumab and radiotherapy in MIBC
3:34
EV-PRIME: enfortumab vedotin, pembrolizumab and radiotherapy in MIBC
Vadim Koshkin • 9 Mar 2026
Patient-reported outcomes in adjuvant renal cell carcinoma therapy
1:01
Patient-reported outcomes in adjuvant renal cell carcinoma therapy
Sophie Merrick • 6 Mar 2026
Late effects and cognitive outcomes in RCC: insights from RAMPART trial
0:51
Late effects and cognitive outcomes in RCC: insights from RAMPART trial
Sophie Merrick • 6 Mar 2026
KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial
2:08
KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial
Sara Coca Membribes • 6 Mar 2026
The content of VJOncology is intended for healthcare professionals